Mirion Technologies, Inc. 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2024. Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis, and monitoring products and services. The company operates in two primary segments: Medical (cancer care, dosimetry, nuclear medicine) and Nuclear & Safety (nuclear power, defense, labs & research). Mirion serves customers in over 120 countries, including 23 of 32 NATO militaries and a significant portion of global nuclear power plants and cancer centers.
Key Financial Metrics (Fiscal Year 2024)
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $860.8 million | $800.9 million | +7.5% |
| Gross Profit | $399.7 million | $356.4 million | +12.1% |
| Gross Margin | 46.4% | 44.5% | +190 bps |
| Operating Income | $24.8 million | ($21.9 million) | Turnaround to Profit |
| Net Loss | ($36.6 million) | ($98.7 million) | 62.9% Improvement |
| Adjusted EBITDA | $203.6 million | $180.7 million | +12.7% |
| Operating Cash Flow | $99.1 million | $95.2 million | +4.1% |
| Total Debt (Principal) | $694.6 million | $694.6 million | No Change |
| Cash & Equivalents | $175.2 million | $128.8 million | +36.0% |
Material Changes vs. Prior Period
- Revenue Growth: Driven by price increases ($15.6M), volume growth ($41.0M), and the full-year impact of the ec 2 Software Solutions acquisition ($11.4M). Growth was partially offset by reduced revenues from China and Russia ($4.7M) and the disposal of the Rehab business ($3.6M).
- Profitability Improvement: The company moved from an operating loss of $21.9 million in 2023 to an operating income of $24.8 million in 2024. This was driven by revenue growth, lower amortization expenses, reduced stock-based compensation, and a significant decrease in the loss from fair value changes of warrant liabilities ($19.5M reduction).
- Segment Performance:
- Medical: Revenue increased 5.3% to $299.7M; Operating income improved to $22.3M (from $13.0M).
- Nuclear & Safety: Revenue increased 8.7% to $561.1M; Operating income improved to $78.9M (from $46.0M), driven by price/volume growth and improved product mix.
- Debt Refinancing: In May 2024, the company amended its credit agreement, reducing the term loan margin rate from 2.75% to 2.25%, lowering the effective interest rate to 6.85% (from 8.40% in 2023).
Guidance, Outlook, and Risks
Outlook & Strategy: Management expects continued growth driven by the nuclear energy renaissance (AI data center power demands, new builds, and upgrades), aging installed base replacement cycles, and expansion in medical dosimetry and radiotherapy. Approximately 54% of the $811.9 million remaining performance obligations are expected to be recognized in 2025.
Key Risks & Contingencies:
- Geopolitical Conflict: Ongoing Russia-Ukraine conflict impacts supply chains and specific projects. A $21 million claim from a Russian customer was settled in November 2024 with an immaterial financial impact. A separate settlement regarding a cancelled Finland project resulted in a refund of €4.4 million.
- Trade Policy: Potential tariffs on imports from China and other regions could increase costs. The company is assessing the impact of new U.S. tariffs announced in early 2025.
- Fixed-Price Contracts: Risks associated with cost overruns on long-term nuclear projects due to inflation or supply chain disruptions.
- Regulatory: Compliance with FDA regulations for medical devices and export controls/sanctions for nuclear products.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the "First Lien Net Leverage Ratio" covenant (max 7.00:1.00) under the 2021 Credit Agreement.
- Warrant Liability Resolution: Confirm the full extinguishment of public and private placement warrant liabilities in Q2 2024 and the associated impact on equity.
- Russia Exposure: Review the status of the $115.5 million remaining performance obligations related to Russian projects and the effectiveness of sanctions compliance.
- Rehab Sale Collection: Monitor the collection of remaining payments from the Biodex Rehab sale to Salona Global, where doubt regarding collectability previously existed.
- Goodwill Valuation: Assess the annual goodwill impairment testing results, noting that the DSD reporting unit had a fair value less than 20% in excess of carrying value in 2024.